Abbott Stops Marketing Weight Loss Drug In Europe

Law360, New York (January 21, 2010, 7:23 PM EST) -- Abbott Laboratories on Thursday suspended the marketing of its weight loss drug in Europe after a European agency indicated the drug increases the risk of heart attack and stroke in patients with cardiovascular problems.

The European Medicines Agency on Thursday advised the Illinois-based drugmaker to stop marketing sibutramine because the benefits of the drug as a weight loss aid are not worth the cardiovascular risks, and asked the European Commission to adopt the recommendation.

The agency also urged doctors to stop prescribing and pharmacists to stop...
To view the full article, register now.